Project description:Standard clinicopathological variables are inadequate for optimal management of prostate cancer patients. While genomic classifiers have improved patient risk classification, the multifocality and heterogeneity of prostate cancer can confound pre-treatment assessment. The objective is to investigate the association of multiparametric (mp)MRI quantitative features with prostate cancer risk gene expression profiles in mpMRI-guided biopsies tissues.
Project description:CTCF ChIP-seq of 39 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011059 (dataset).
Project description:Patients receiving radiation therapy for prostate cancer received a multiparametric MRI and MRI/ultrasound-fusion targeted biopsy. Patients received a second mpMRI six months after radiation therapy. The goal of this study was to generate gene expression profiles of prostate cancer tumor tissue prior to treatment, and compare the gene expression profiles of those patients based on imaging response or time to biochemical recurrence.
Project description:H3K27ac ChIP-seq of 79 primary samples derived from human acute leukemias, namely AML, T-ALL and mixed myeloid/lymphoid leukemias with CpG Island Methylator Phenotype (CIMP). In addition, 4 samples derived from CD34+ cord blood cells of healthy donors were included. Due to patient confidentiality considerations, the raw data files for this dataset have been deposited to the EGA controlled-access archive under the accession numbers EGAS00001007094 (study); EGAD00001011060 (dataset).
Project description:Genome wide DNA methylation profiling of a suite of biological samples for technical evaluation of the HumanMethylationEPIC v2.0 BeadChip. Samples include prostate (LNCaP, PrEC) and breast cancer (MCF7, TAMR) cell lines, as well as primary tumour samples from prostate (SYN*) and breast (FD*).
Project description:Proteomics analysis of matched tumor and normal adjacent tumor regions of 40 patients with multiparametric magnetic resonance imaging (mpMRI) visible or invisible tumors. All patients have clinically significant intermediate-risk (pathological ISUP Grade Group 2), localized prostate cancer.
Project description:Genome wide DNA methylation profiling of a suite of biological samples for technical evaluation of the HumanMethylationEPIC v2.0 BeadChip. Samples include prostate (LNCaP, PrEC) and breast cancer (MCF7, TAMR) cell lines, as well as primary tumour samples from prostate (SYN*) and breast (HCI*|Gar*).
Project description:Genome wide DNA methylation profiling of a suite of biological samples for technical evaluation of the HumanMethylationEPIC v2.0 BeadChip. Samples include prostate (LNCaP, PrEC) and breast cancer (MCF7, TAMR) cell lines, as well as primary tumour samples from prostate (SYN*) and breast (HCI*|Gar*).
Project description:The purpose of this study was to develop better ways of detecting prostate cancer before and after pre-operative treatment, and to test the feasibility of multi parametric magnetic resonance imaging (mpMRI) for the localization and detection of focal prostate cancer both before and after pre-operative treatment with ADT and enzalutamide. In this study, patients with intermediate and high risk prostate cancer received six months of neoadjuvant intense androgen deprivation therapy prior to radical prostatectomy. Biopsies were acquired prior to treatment. Tissue from biopsy and radical prostatectomy were subjected to sequencing and analysis for determination of features associated with response or resistance to treatment.
